Table 1.

General clinical data, laboratory examinations, and prognosis of 41 severely ill COVID-19 patients.

	Severe cases (n = 23)	Severe-to-critical cases (n = 18)	P
Age, y	61.1 (32–81)	71.0 (46–90)	.024
Sex
Male	13 (56.5%)	12 (66.7%)	.509
Underlying diseases
Hypertension	7 (30.4%)	6 (33.3%)	.843
Diabetes	2 (8.7%)	4 (22.2%)	.224
Heart disease	4 (17.4%)	7 (38.9%)	.123
Chronic obstructive pulmonary disease	1 (4.3%)	1 (5.6%)	.859
Cerebrovascular disease	3 (13.0%)	1 (5.6%)	.423
≥2 underlying diseases	4 (17.4%)	8 (44.4%)	.059
Clinical symptoms and APACHE II score
Fever	20 (87.0%)	16 (88.9%)	.851
Cough	15 (65.2%)	13 (72.2%)	.632
Difficulty breathing	21 (91.3%)	17 (94.4%)	.702
APACHE II score	13.3 (9–16)	15.1 (12–19)	.647
Laboratory examination results
WBC count at hospital admission, ×109 cells/L	5.5 (4.2–7.8)	6.1 (4.4–8.3)	.478
Neutrophil count at hospital admission, ×109 cells/L	4.2 (2.8–6.2)	4.7 (2.9–7.4)	.545
Elevated neutrophil count	11 (47.8%)	15 (83.3%)	.019
Lymphocyte count at hospital admission, ×109 cells/L	0.7 (0.4–0.9)	0.6 (0.3–0.7)	.638
Reduced lymphocyte count	9 (39.1%)	13 (72.2%)	.035
Days between severe and critical illness		11.6 (6–18)
Fatalities	0	12 (66.7%)